Manages Diabetes Efficiently


COMPOSITION: Pioglitazone HCI 15 mg + Metformin HCI 500 mg (ER)


  • Type-II Diabetes Mellitus
  • Diabetes Mellitus with Obesity

Pioglitazone HCI (Thiazolidinediones/ glitazones)

  • Improves glycemic control while reducing circulating insulin levels.
  • Significantly affects Glycated Haemoglobin (HbA1c) and FPG (Fasting Plasma Glucose) while producing beneficial effects on serum lipids.

Metformin HCI (Biguanides)

  • Effectively reduces BMI and insulin resistance in hyperinsulinemic obese adolescents and children.


  • The insulin sensitizers, both metformin, and glitazones are mainly used in subjects with type 2 diabetes who are obese.
  • Metformin and pioglitazone had beneficial effects on lipid levels, improved insulin sensitivity, and improved insulin secretion also.
  • Metformin and pioglitazone were useful in reducing postprandial hyperglycemia.
  • Mean cholesterol decreased significantly in groups treated with metformin and pioglitazone.
  • HDL-cholesterol increased with pioglitazone. Insulin resistance decreased significantly with metformin and pioglitazone, and β cell function also showed improvement.